GMA as A Therapeutic Target for Cancer and Neurodegenerative Diseases

Target Name: GM2A

NCBI ID: G2760

GM2A

GMA as A Therapeutic Target for Cancer and Neurodegenerative Diseases

Ganglioside GM2 (GMA) is a type of sialic acid found on the surface of many different cell types in the body. It is a key component of the cell-cell adhesion complex, which is responsible for maintaining tissue structure and function. GMA plays a crucial role in this process, and its levels have been shown to be involved in a wide range of physiological processes in the body.

Recent studies have identified GMA as a potential drug target, or biomarker, due to its involvement in various diseases and disorders. In this article, we will explore the biology and potential therapeutic applications of GMA, with a focus on its role as a drug target.

GMA and Cell-Cell Adhesion

GMA is a key component of the cell-cell adhesion complex, which is a complex of adhesion molecules that help to maintain tissue structure and function. This complex includes proteins such as cadherin, which is a transmembrane protein that is involved in cell-cell adhesion , and integrin, which is a cytoplasmic protein that is involved in the formation of tight junctions.

GMA plays a crucial role in the cell-cell adhesion complex by helping to regulate the interactions between adhesion molecules. It does this by modulating the activity of various enzymes that are involved in this process, including tyrosine phosphorylation and calcification.

GMA and Disease

GMA has been shown to be involved in a wide range of diseases and disorders, including cancer, neurodegenerative diseases, and autoimmune diseases.

One of the main challenges in studying GMA and its role in disease is its complex biochemical pathways. GMA is involved in many different signaling pathways, and it is difficult to identify the precise mechanisms by which it contributes to disease.

However, research has shown that GMA is involved in several key signaling pathways that are involved in disease. For example, GMA has been shown to be involved in the development and progression of cancer, by contributing to the regulation of cell cycle progression and the maintenance of stem cell self-renewal.

GMA has also been shown to be involved in the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. These conditions are characterized by the progressive loss of brain cells, and GMA has been shown to play a role in the regulation of neurodegeneration.

GMA and Therapeutic Applications

GMA has the potential to be a drug target or biomarker for a wide range of therapeutic applications. One of the main strategies for targeting GMA is to use small molecules that can modulate its activity.

One of the most promising small molecules is called GX1120, which is a GMA inhibitor that has been shown to have anti-tumor effects in animal models of cancer. GX1120 works by inhibiting the activity of a protein called FAK, which is involved in cell- cell adhesion and has been shown to contribute to the development of cancer.

Another small molecule that has potential as a GMA inhibitor is called BHV-3500, which is an inhibitor of the protein TrkA, which is involved in the regulation of cell-cell adhesion. BHV-3500 has been shown to have anti-tumor effects in animal models of cancer, and may be a promising therapeutic for the treatment of cancer.

In addition to small molecules, another potential approach for targeting GMA is to use antibodies that can specifically recognize and target the protein itself. This approach has the advantage of being highly specific, and can be used to treat diseases where GMA is highly expressed, such as cancer.

Conclusion

Ganglioside GM2 (GMA) is a key component of the cell-cell adhesion

Protein Name: Ganglioside GM2 Activator

Functions: The large binding pocket can accommodate several single chain phospholipids and fatty acids, GM2A also exhibits some calcium-independent phospholipase activity (By similarity). Binds gangliosides and stimulates ganglioside GM2 degradation. It stimulates only the breakdown of ganglioside GM2 and glycolipid GA2 by beta-hexosaminidase A. It extracts single GM2 molecules from membranes and presents them in soluble form to beta-hexosaminidase A for cleavage of N-acetyl-D-galactosamine and conversion to GM3 (By similarity). Has cholesterol transfer activity (PubMed:17552909)

The "GM2A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GM2A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets